Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.

Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A.

Endocr Res. 2015;40(3):133-8. doi: 10.3109/07435800.2014.966385. Epub 2014 Oct 20.

PMID:
25330463
3.

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.

Ferjan S, Janez A, Jensterle M.

Metab Syndr Relat Disord. 2017 Dec;15(10):515-520. doi: 10.1089/met.2017.0095. Epub 2017 Oct 24.

PMID:
29064743
4.

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.

Jensterle M, Kravos NA, Goričar K, Janez A.

BMC Endocr Disord. 2017 Jan 31;17(1):5. doi: 10.1186/s12902-017-0155-9.

5.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

6.
7.

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A.

Eur J Endocrinol. 2014 Feb 7;170(3):451-9. doi: 10.1530/EJE-13-0797. Print 2014 Mar.

8.

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2012 Sep 14;11:107.

9.

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.

J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74.

PMID:
10946879
10.

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.

Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J.

Diabetes Obes Metab. 2018 Jan;20(1):215-218. doi: 10.1111/dom.13053. Epub 2017 Aug 11.

PMID:
28681988
11.

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.

de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K.

Int J Clin Pharm. 2016 Feb;38(1):144-51. doi: 10.1007/s11096-015-0219-8. Epub 2015 Nov 23.

12.

GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.

Lamos EM, Malek R, Davis SN.

Expert Rev Clin Pharmacol. 2017 Apr;10(4):401-408. doi: 10.1080/17512433.2017.1292125. Epub 2017 Feb 13. Review.

PMID:
28276778
13.

Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.

Jensterle M, Pirš B, Goričar K, Dolžan V, Janež A.

Eur J Clin Pharmacol. 2015 Jul;71(7):817-24. doi: 10.1007/s00228-015-1868-1. Epub 2015 May 21.

PMID:
25991051
14.

Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.

Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E.

Eur J Endocrinol. 2018 Jul;179(1):1-11. doi: 10.1530/EJE-18-0175. Epub 2018 Apr 27.

PMID:
29703793
15.

Dietary intake, eating behaviors, and quality of life in women with polycystic ovary syndrome who are trying to conceive.

Turner-McGrievy G, Davidson CR, Billings DL.

Hum Fertil (Camb). 2015 Mar;18(1):16-21. doi: 10.3109/14647273.2014.922704. Epub 2014 Jun 12.

PMID:
24921163
16.

A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.

Niafar M, Pourafkari L, Porhomayon J, Nader N.

Arch Gynecol Obstet. 2016 Mar;293(3):509-15. doi: 10.1007/s00404-015-3976-7. Epub 2015 Dec 10. Review.

PMID:
26660657
17.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.

Tzotzas T, Karras SN, Katsiki N.

Curr Vasc Pharmacol. 2017;15(3):218-229. doi: 10.2174/1570161114666161221115324. Review.

PMID:
28003008
18.

Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome.

Larsson I, Hulthén L, Landén M, Pålsson E, Janson P, Stener-Victorin E.

Clin Nutr. 2016 Feb;35(1):213-8. doi: 10.1016/j.clnu.2015.02.006. Epub 2015 Feb 20.

PMID:
25743212
19.

Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.

Jensterle M, Kocjan T, Janez A.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1476-81. doi: 10.1210/jc.2014-1430. Epub 2014 May 13.

PMID:
24823465
20.

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL.

BMC Endocr Disord. 2015 Apr 2;15:14. doi: 10.1186/s12902-015-0005-6.

Supplemental Content

Support Center